C. Jillian Tsai, MD, PhD
@CJTsaiMDPhD
Lead, Allan & Ruth Kerbel Palliative RT/Oligomet Program (PROP) @PMcancercentre @RadMedPM @UHN. Via @MSKCancerCenter @MDAndersonNews. HN/skin/metastatic cancers
🚨📢🌟 CURB2 Ph3 Trial is activated by @NCICTEP_ClinRes (NCT06686771), built upon CURB Ph2 RCT @TheLancet/@MSKCancerCenter. Appreciate the support of @NRGonc/@SWOG/@CCTG. Pls contact us for activation at your local site❗️ @pmcancercentre @ldawsonmd @DrAlexLouie @HoudaBahig


The PROP (Pall RT & Oligomet Progeam) @pmcancercentre @UHN would not be successful without our #APRT (previously CSRT). They play a vital role in patient care and clinical trials. Would love to see an expansion of such endeavor. @YatTsang @DKirschMDPhD @ldawsonmd
Is it time to rethink the role of the RTT in U.S. #RadOnc? What is an Advanced Practice Radiation Therapist (APRT)? Globally, APRTs are stepping into expanded roles—but in the U.S., that concept doesn’t yet exist. Should it? Let’s break it down. 🧵 #RadiationTherapy #APRT 1/7
En route to @NRGonc and will speak with colleagues about updates of @CDNCancerTrials @NCICancerTrials #CURB2 trial. This sign at the airport seems fitting! @KHigginsMD @JeffBradleyMD @UofTDRO @RadMedPM

🎉 Just announced: A huge congrats to #RMPatPM staff @ScottBratman @CJTsaiMDPhD Dr. Philip Wong @DKirschMDPhD @MKoritzinsky who received over $3.5 million in @CIHR_IRSC funding for their cutting-edge radiation research. See highlights below⤵️
🚨🚨🚨 We are activating this single-arm phase 2 trial of hypofractionated RT to oligoprogressive metastatic #melanoma, up to 10 lesions + extensive specimen collection for correlatives. There's an unmet need in this area - hope results of the trial will benefit more patients.



⏰ A critical read about how small changes can have significant consequences. Data manipulation within the US Federal Government - The Lancet thelancet.com/journals/lance…
Interesting paper, although I wouldn't have included CURB since it's not OMD. Also would include LU002. Efficacy and Safety of Metastatic Directed Treatment of Oligometastatic Disease: Results of a Meta-analysis - Advances in Radiation Oncology advancesradonc.org/article/S2452-…

Congrats @RebeccaKSWong @RadMedPM @pmcancercentre @UHN! @DKirschMDPhD @ldawsonmd
🚨🚨 Just announced: 43 distinguished members named ASTRO Fellow Congratulations to all & thank you for your contributions to ASTRO & the specialty! 🎉🎉🎉 ow.ly/1rKh50WnhSn
p-Values and confidence intervals as compatibility measures: guidelines for interpreting statistical studies in clinical research - The Lancet Regional Health - Southeast Asia thelancet.com/journals/lanse…
Interesting images for all the HN surgeons! Frostbite Injury from Inhaled Nitrous Oxide Use | New England Journal of Medicine nejm.org/doi/full/10.10…

👀Not cancer but promising concept/result. As we expand the indication of #radiotherapy this could be an area of active interest. @SameerKeoleMD @ASTRO_org thelancet.com/journals/lance…

🚨Advanced Pract Radiation Therapist🚨 🌟 #APRT @JoannaJavor of Allan & Ruth Kerbel Pall RT/Oligomet Program (PROP) presented data of sim-free RT (incl single fx #SBRT 12-20Gy). Best wishes for her med school pursuit! 🔥 📢📢PS. We will be looking for an #APRT. PM me for details.

Hilarious. 😂 Should add that if p>0.05 some might change endpoint and re-analyze! This is just unthinkable when in grad school the mere mention of p value will give us negative points in exams!
How to interpret p-values 😅
👋👋👋Final hour of #ELIXR25 Jeopardy - which team will win? Is it team 🇪🇺or 🇨🇦 or 🇺🇸?




☀️Day2 #ELIXR conference - patient-centered discussions in the morning. @pompili_cecilia presenting the dire needs and challenges of obtaining comprehensive assessment of QOL/PRO.


✅👍🏻Day1 of ELIXR25 - stellar lineup of speakers and panelists! As a clinical trialist focusing on metastatic lung cancer/biomarkers, this conference has been truly informative! 👋🏻👋🏻👋🏻 Looking forward to Day2!!!




Kicking off our annual HN Wharton/Elia Day lecture series with an inspiring talk by @imrtlee @MSKCancerCenter. Grateful for the generous support from the donors and patient volunteers. @thePMCF

It is most gratifying to see talented young physicians successfully complete their residency/fellowship training. Congratulations to our new graduates! @ldawsonmd




Together, we raised $20.61 million to support life-saving cancer research and patient care! Congratulations and thank you to the 4,400+ cyclists who participated in @thePMCF's 2025 Ride to Conquer Cancer presented by Johnson & Johnson! 🚴♂️🙌 Read more: uhn.ca/corporate/news…
Over 4,400 cyclists participated in the 18th annual Ride to Conquer Cancer presented by Johnson & Johnson. Together, we raised a record-breaking $20.61 million to support life-saving cancer research and patient care at UHN's @pmcancercentre. Read more: uhn.ca/corporate/news…
📕It was a fantastic experience working with @BenjaminKannMD @anantm et al on this emerging topic. Free access paper here 👉tinyurl.com/4rd2c4kn @ASCO_pubs
Thrilled to share new @ASCO Educational Book Chapter! 📖🤖 AI for head & neck cancer—diagnosis to personalized treatment. 🔹 Better tumor diagnosis & prognosis 🔹 Multimodal AI for survival prediction 🔹 Early toxicity & complication detection Paper: tinyurl.com/4rd2c4kn